Department of Pharmacology, University of Cape Town, Medical School, Observatory, 7925 Cape Town, South Africa.
J Pharm Biomed Anal. 2011 May 15;55(2):373-8. doi: 10.1016/j.jpba.2011.01.036. Epub 2011 Feb 4.
A solvent extraction method was developed and validated for the determination of the antimalarial drug, artemether and its active metabolite dihydroartemisinin (DHA) in malaria patient plasma samples. An AB Sciex 4000 triple quadrupole mass spectrometer in the multiple reaction monitoring (MRM) mode was used for detection in the positive ionisation mode. Liquid-liquid extraction was followed by PFP liquid chromatography and tandem mass spectrometry. Stable isotope labelled artemether and DHA was used as internal standards. The calibration range was between 2.00 and 500 ng/ml for both artemether and DHA during the original validation and the upper limit was lowered to 200 ng/ml during a re-instatement validation, prior to sample analysis. The assay was used to measure artemether and DHA in human plasma samples, which were generated from a safety and efficacy clinical trial in Mbarara, Uganda; as well as for a pharmacokinetic interaction study between the antimalarial combination artemether/lumefantrine and combination antiretroviral therapy including nevirapine in HIV-infected adults.
建立并验证了一种溶剂萃取法,用于测定疟疾患者血浆样本中的抗疟药物青蒿素及其活性代谢物双氢青蒿素(DHA)。采用 AB Sciex 4000 三重四极杆质谱仪,在正离子化模式下,以多反应监测(MRM)模式进行检测。采用液-液萃取法,再经 PFP 液相色谱和串联质谱进行分析。采用稳定同位素标记的青蒿素和 DHA 作为内标。在最初的验证中,青蒿素和 DHA 的校准范围为 2.00 至 500ng/ml,在重新进行验证时,在进行样品分析之前,上限降低至 200ng/ml。该检测方法用于测定乌干达姆巴拉拉安全性和疗效临床试验中生成的人血浆样本中的青蒿素和 DHA,以及抗疟药青蒿素/咯萘啶联合疗法与包括奈韦拉平在内的抗逆转录病毒联合疗法之间的药代动力学相互作用研究。